日本新薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4516/E00931 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2015/04/17 | 日証協 | 378,837株 | -0.99% | 37,000株 | -39.49% | 401,794株 | -3.04% | 25,000株 | +96.85% |
2015/04/10 | 日証協 | 382,623株 | -20.56% | 61,147株 | -78.26% | 414,399株 | -20.58% | 12,700株 | -95.42% |
2015/04/03 | 日証協 | 481,648株 | -20.4% | 281,305株 | -46.67% | 521,794株 | -24.95% | 277,406株 | -37.72% |
2015/03/20 | 日証協 | 472,671株 | -13.59% | 232,653株 | -3.86% | 507,843株 | -25.2% | 24,898株 | -85.67% |
2015/03/13 | 日証協 | 547,018株 | +30.25% | 242,000株 | -6.2% | 678,945株 | +31.35% | 173,700株 | +46.39% |
2015/03/06 | 日証協 | 419,986株 | +1.28% | 258,000株 | +6.49% | 516,913株 | +6.75% | 118,653株 | +196.63% |
2015/02/27 | 日証協 | 414,673株 | -24.57% | 242,268株 | +7.98% | 484,247株 | -17.04% | 40,000株 | -20% |
2015/02/20 | 日証協 | 549,711株 | -19.83% | 224,372株 | +280.29% | 583,711株 | -4.17% | 50,000株 | +59.36% |
2015/02/13 | 日証協 | 685,711株 | -2.2% | 59,000株 | -76.48% | 609,087株 | -13.07% | 31,376株 | -71.34% |
2015/02/06 | 日証協 | 701,150株 | -0.02% | 250,884株 | -16.51% | 700,625株 | +1.45% | 109,458株 | +132.89% |
2015/01/30 | 日証協 | 701,308株 | +1.11% | 300,504株 | +637.2% | 690,625株 | -0.84% | 47,000株 | -45.02% |
2015/01/23 | 日証協 | 693,606株 | -2.38% | 40,763株 | -83.69% | 696,503株 | +3.16% | 85,478株 | +0.43% |
2015/01/16 | 日証協 | 710,514株 | -2.66% | 249,903株 | +2% | 675,140株 | +1.07% | 85,115株 | +156.02% |
2015/01/09 | 日証協 | 729,934株 | +1.56% | 245,000株 | +338.66% | 667,986株 | +4.5% | 33,245株 | -36.07% |
2014/12/30 | 日証協 | 718,748株 | +4.46% | 55,852株 | +8.67% | 639,231株 | +5.22% | 52,000株 | -6.72% |
2014/12/26 | 日証協 | 688,081株 | +4.36% | 51,398株 | -76% | 607,532株 | +2.36% | 55,745株 | +16.69% |
2014/12/19 | 日証協 | 659,357株 | -4.64% | 214,189株 | -14.71% | 593,534株 | +1.22% | 47,772株 | -68.15% |
2014/12/12 | 日証協 | 691,476株 | -3.88% | 251,119株 | +23.73% | 586,359株 | -16.29% | 150,000株 | +29.4% |
2014/12/05 | 日証協 | 719,419株 | -8.75% | 202,965株 | -55.64% | 700,459株 | -4.11% | 115,924株 | -19.5% |
※株式分割は考慮していませんのでご注意ください。
Page Top